United Cannabis Granted Patent for Its Prana Bio Nutrient Line of Cannabinoid Based Products in the United States
August 15 2017 - 4:15PM
Access Wire
DENVER, CO / ACCESSWIRE / August 15, 2017 /
United Cannabis Corporation (OTCQB: CNAB) (the "Company" or "United
Cannabis") today announced that the United States Patent and
Trademark Office (USPTO) has issued US Patent #9730911 (the
"Patent"), granting exclusive rights to its proprietary
formulations based on compounds extracted from cannabis plant
materials; more specifically, the composition of matter pertaining
to the use of phytocannabinoids, cannabinoids, and specific terpene
profiles in liquid form. This composition of matter patent provides
protection for United Cannabis' proprietary formulations.
Earnest Blackmon, United Cannabis' Chief Executive Officer,
commented on the approval, "This is a significant milestone for
United Cannabis. Our primary objective has always been to develop
unique and effective cannabinoid based products. This Patent is one
the cornerstones of our business plan for obtaining FDA
approval."
Tony Verzura, the Company's Chief Technology Officer, added, "I
have spent the last 20 years working with cannabis as a patient,
activist, caregiver, and innovator. Our patented innovations
enabled our team to utilize chemical-free extractions and infusion
methodologies for a wide range of accurately dosed products. These
advances have helped us provide relief for thousands of patients
suffering from a variety of ailments."
The patent protects the use of suspending both phytocannabinoids
and cannabinoids with specific combinations of cannabis derived
terpenes in liquid forms with an array of delivery methods
including capsule, sublingual, topical, oral, suppository, and
vaporization. Cannabinoids referenced in the application include
ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid
(CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol
(CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC).
About United Cannabis Corporation
United Cannabis Corporation is a biotechnology company dedicated
to the development of phyto-therapeutic based products supported by
patented technologies for the pharmaceutical, medical, and
industrial markets. The Company has long advocated the application
of cannabinoids for medical applications and is building a platform
for designing targeted therapies to increase the quality of life
for patients around the world. The Company's products are patent
protected, first in class medicines with applications to a global
market. United Cannabis trades on the OTCQB under the symbol
CNAB.
For further information, please visit www.unitedcannabis.us.
Contact:
Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933, and are subject to Rule 3b-6 under the
Securities Exchange Act of 1934, and are subject to the safe
harbors, created by those rules. All statements, other than
statements of fact, included in this release, including, without
limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and other results and
further events could differ materially from those anticipated in
such statements. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements.
SOURCE: United Cannabis Corporation